4//SEC Filing
Zalevsky Jonathan 4
Accession 0001193125-25-297855
CIK 0000906709other
Filed
Nov 24, 7:00 PM ET
Accepted
Nov 25, 8:30 PM ET
Size
10.4 KB
Accession
0001193125-25-297855
Insider Transaction Report
Form 4
Zalevsky Jonathan
Chief R&D Officer
Transactions
- Award
Stock Option
2025-11-21+4,766→ 4,766 totalExercise: $281.25Exp: 2028-12-17→ Common Stock (4,766 underlying) - Sale
Common Stock
2025-11-25$54.28/sh−1,157$62,802→ 18,971 total - Award
Common Stock
2025-11-21+2,666→ 20,128 total
Footnotes (6)
- [F1]Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 18, 2020 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant.
- [F2]The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 20, 2025 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on November 21, 2025.
- [F3]Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
- [F4]This transaction was executed in multiple trades at prices ranging from $58.26 to $59.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
- [F5]These stock options were granted on December 18, 2020 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of four years from the date of grant.
- [F6]The Compensation Committee determined on November 20, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on November 21, 2025.
Documents
Issuer
NEKTAR THERAPEUTICS
CIK 0000906709
Entity typeother
Related Parties
1- filerCIK 0001789857
Filing Metadata
- Form type
- 4
- Filed
- Nov 24, 7:00 PM ET
- Accepted
- Nov 25, 8:30 PM ET
- Size
- 10.4 KB